In Vitro Antimicrobial Activity of Novel Antimicrobial Peptide OMN51 Against Multi-drug Resistant Pseudomonas

Collaboration with Beilinson – Rabin Medical Center’s Cystic Fibrosis Clinic

Omnix Medical has successfully completed a year-long collaboration with the Adult CF and Bronchiectasis Clinic, led by Dr. Moshe Heching at Beilinson-Rabin Medical Center. Results were presented recently in a poster during the last North American Cystic fibrosis conference (NACFC).

The collaboration showcased the effectiveness of Omnix’s innovative antimicrobial peptide, OMN51, in combating antibiotic-resistant bacteria in CF patients. The study evaluated the in vitro activity of OMN51 against dozens Pseudomonas aeruginosa strains isolated from people with CF. OMN51 demonstrated potent bactericidal activity across susceptible, resistant, and MDR strains with no observed resistance or cross-resistance. These findings support OMN-51’s potential as a promising therapeutic candidate.

View Poster: In Vitro Activity of Novel Peptide OMN51 on Multidrug Resistant Pseudomonas

Authors: Moshe Heching, Haim Ben Zvi, Rivka Glick, Liora Slomiansky, Joel Weinberg, Michal Oholy, Rony Moses, Noa Nur Maymon, Elital Chass Maurice, Shira Mandel, Moshik Cohen-Kutner, Niv Bachnoff, Mordechai R Kramer